Atypical Chronic Myeloid Leukemia (aCML): A Patient Guide

Atypical Chronic Myeloid Leukemia (aCML) is a rare and complex blood cancer that exists at the intersection of two different types of disorders. It is classified as an MDS/MPN overlap syndrome, meaning the bone marrow behaves as if it has two different problems at once: it overproduces white blood cells, a hallmark of Myeloproliferative Neoplasms (MPN), but those cells are also misshapen and defective, a feature of Myelodysplastic Syndromes (MDS) ^[1]. This combined process leads to a high number of white blood cells that do not function correctly, often causing symptoms like fatigue, anemia, or an enlarged spleen ^[2].

One of the most important things to understand is that despite the name, aCML is fundamentally different from “classic” Chronic Myeloid Leukemia. Classic CML is driven by a specific chromosomal rearrangement called the Philadelphia Chromosome or BCR::ABL1 fusion ^[3]. Atypical CML requires the absence of this fusion. Because of this, BCR::ABL1-directed targeted therapies (like imatinib) are not routinely effective or indicated for this condition ^[4]. Instead, the diagnosis relies on an integrated clinical evaluation that includes blood cell counts, bone marrow morphology, molecular testing, and the careful exclusion of other myeloid neoplasms.

Given that aCML is an ultra-rare condition, the experience of your medical team is paramount. Many local oncology clinics may rarely encounter this diagnosis, making it vital to connect with a specialized leukemia center or an MDS/MPN expert who is familiar with the latest research ^[5]. These specialists use advanced genetic testing, such as Next-Generation Sequencing (NGS), to identify supportive mutations that help clarify the diagnosis and prognosis, or to determine clinical trial eligibility ^[4][6].

While there are medications available to help control blood counts and manage day-to-day symptoms, an Allogeneic Stem Cell Transplant currently remains the only established potentially curative option. Because the success of a transplant often depends on the patient’s fitness and disease status, early consultation with a transplant specialist is a proactive part of the orientation process ^[7][8]. Navigating this diagnosis is a significant undertaking, but as our understanding of aCML grows, specialized teams can provide more informed and supportive care ^[9].